Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial
Author:
Ian E Krop,Sung-Bae Kim,Antonio Gonzalez Martin,Patricia M LoRusso,Jean-Marc Ferrero,Tanja Badovinac-Crnjevic,Silke Hoersch,Melanie Smitt,Hans Wildiers
Publication:
The Lancet Oncology
© 2017 Elsevier Ltd. All rights reserved.